^
Association details:
Biomarker:EGFR L858R
Cancer:Non Small Cell Lung Cancer
Drug Class:Angiogenesis inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

Published date:
08/26/2022
Excerpt:
Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent.
DOI:
https://doi.org/10.1038/s41598-022-18889-z